The Future of Heart Disease Prevention Begins Now
Heart disease remains the world’s leading cause of death, claiming more than 17 million lives each year. Most heart attacks occur without any clear warning signs. But what if doctors could see the danger years before it struck?
That question lies at the core of a medical breakthrough from Caristo Diagnostics, a UK-based company that has developed an artificial intelligence system capable of predicting heart attacks up to 10 years before they occur.
Born from research at Oxford University, Caristo’s innovation could completely reshape preventive cardiology. Their AI-powered tool, known as CaRi-Heart®, uses existing heart scan data to detect inflammation around coronary arteries, one of the earliest and most powerful indicators of future cardiac events.
This revolutionary step marks the shift from reactive medicine to predictive care — allowing doctors to treat patients long before a heart attack ever happens.
The Science Behind the Breakthrough
Traditional coronary computed tomography angiography (CCTA) scans help doctors view blockages or narrowing in arteries. However, these scans often miss the hidden signs of inflammation — the “invisible fire” that quietly damages arteries and leads to heart attacks.
Caristo Diagnostics’ technology takes this same scan and looks deeper. The CaRi-Heart® AI algorithm measures subtle changes in the fat tissue surrounding coronary arteries using a proprietary biomarker called the FAI-Score™ (Fat Attenuation Index).
This score reveals the level of inflammation inside the artery walls — even when plaque or blockages are not yet visible. It’s a critical advancement, because inflammation is often the first sign of heart disease and the main reason plaque becomes unstable and ruptures, causing sudden heart attacks.
Within minutes, the AI processes the CCTA scan, calculates the FAI-Score, and provides a personalized 10-year heart attack risk profile.
Doctors can use this data to start preventive treatment early, such as prescribing statins, recommending lifestyle changes, or performing closer monitoring.
“We can now detect the fire before the smoke,” explains Professor Charalambos Antoniades, founder and CEO of Caristo Diagnostics. “Our mission is to identify risk before disease strikes — and save lives through prevention.”
Clinical Evidence: The Lancet Study
Caristo’s technology isn’t just a concept; it’s backed by world-class clinical research.
In 2024, results from the ORFAN study were published in The Lancet, one of the world’s most respected medical journals.
The study followed thousands of patients who underwent CCTA scans. Researchers discovered that the FAI-Score™ was a powerful and independent predictor of major cardiac events for up to 10 years.
Patients with higher FAI-Score values were significantly more likely to experience a heart attack, even when their arteries appeared clear in traditional scans.
This finding has positioned Caristo’s AI as one of the most accurate tools ever developed for long-term cardiac risk prediction — far beyond what cholesterol tests or stress ECGs can provide.
From the UK to the U.S. — FDA Clearance Marks a New Chapter
In March 2025, Caristo Diagnostics achieved a major milestone when the U.S. Food and Drug Administration (FDA) granted 510(k) clearance to its CaRi-Plaque™ software.
This companion tool analyzes plaque composition and structure within arteries to help identify unstable or high-risk plaques.
The company is now preparing to introduce its flagship CaRi-Heart® AI system to the U.S. healthcare market. Early pilot programs are already underway at leading American hospitals, where cardiologists are integrating Caristo’s technology into routine heart scan workflows.
“This is a game-changer for preventive cardiology,” said one U.S. clinician involved in early trials. “We finally have a tool that looks beyond the visible blockage and tells us what’s really happening inside the artery walls.”
Once fully approved, Caristo’s AI could be available in hospitals across the United States — potentially transforming how heart disease is diagnosed and prevented.
Why This Matters for Patients
Heart attacks often come without warning, even in people with no obvious symptoms.
Traditional risk assessment tools, such as cholesterol levels and family history, only tell part of the story. They cannot visualize inflammation or subtle damage that happens years before a heart attack occurs.
That’s where Caristo’s AI steps in.
By detecting inflammation early, doctors can identify which patients are silently at risk and start treatment immediately.
This proactive approach has the power to save lives, reduce healthcare costs, and bring peace of mind to millions.
For patients, this means a single scan could unlock a decade of insight into their future heart health.
Instead of waiting for symptoms, they can act today to prevent tomorrow’s crisis.
The Road Ahead: Global Expansion and Future Innovation
Caristo Diagnostics is already expanding across Europe and North America.
The company is also in discussions with partners in Asia, the Middle East, and India, where cardiovascular disease rates are rapidly increasing.
Future versions of the CaRi-Heart system are expected to integrate data from genetics, blood biomarkers, and lifestyle factors, creating a complete predictive model for heart health.
By combining AI imaging with broader health data, Caristo aims to give every person a personalized map of their cardiovascular future.
The company’s vision is bold yet clear — to shift the world’s focus from treating heart disease to preventing it before it starts.
“We see a future where no one dies of a heart attack that could have been prevented,” said Professor Antoniades. “That future is closer than we think.”
A Turning Point in Medicine
The introduction of Caristo’s AI marks one of the most significant milestones in modern cardiology.
For decades, doctors have treated heart disease reactively — responding only after damage occurs.
Now, with the help of advanced artificial intelligence, medicine is entering an age where prediction and prevention take center stage.
Caristo Diagnostics stands at the forefront of that transformation, offering a technology that doesn’t just detect disease — it foresees it.
And for millions at risk of heart disease, that could mean the difference between life and death.